logo

Citius Pharmaceuticals, Inc. (CTXR)



Trade CTXR now with
  Date
  Headline
5/6/2022 9:39:10 AM Citius Pharma To Accelerate Phase 3 Mino-Lok Trial By Expanding Trial Sites Internationally
5/3/2022 10:11:04 AM Citius Anticipates Filing BLA For I/ONTAK With FDA In H2 Of 2022
4/6/2022 6:58:07 AM Citius Pharma Reports Topline Data From Phase 3 Study Of Cancer Immunotherapy I/ONTAK For Persistent Or Recurrent CTCL
2/15/2022 9:22:11 AM Citius : FDA Accepts IND Application For Phase 2b Study Of Halo-Lido For Prescription Treatment Of Hemorrhoids
12/6/2021 9:17:53 AM Citius Completes Enrollment In Phase 3 Study Of Cancer Immunotherapy I/ONTAK For Treatment Of Cutaneous T-Cell Lymphoma
11/5/2021 9:17:19 AM Citius Pharmaceuticals Appoints Kelly Creighton As EVP Of Chemistry, Manufacturing And Controls
9/7/2021 7:32:42 AM Citius Buys Dr. Reddy's License For Late-Phase 3 Oncology Immunotherapy For Treatment Of CTCL, Other Cancer Indications
7/1/2021 9:02:19 AM Citius Announces Positive Recommendation By Independent Data Monitoring Committee To Continue Mino-Lok Phase 3 Trial
4/29/2021 9:38:45 AM Citius Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar
2/17/2021 12:36:15 AM Citius Pharmaceuticals Announces $76.5 Mln Registered Direct Offering Priced At-the-Market Under Nasdaq Rules